Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Why the Immuron (ASX:IMC) share price rocketed another 17% today
Here’s why the Immuron (ASX:IMC) share price is rocketing 31% today
Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data
Why the Immuron (ASX:IMC) share price is surging 8% higher
Share Market News
Why the Immuron (ASX:IMC) share price fell today
Share Market News
Why the Immuron (ASX:IMC) share price is rocketing up 10% today
Share Market News
Why the Immuron (ASX:IMC) share price is rocketing 18% higher today
Share Market News
Afterpay and Immuron were among the most traded shares on the ASX last week
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
|16 May 2022||$0.11||$0.01||9.52%||64,348||$0.11||$0.11||$0.11|
|13 May 2022||$0.11||$-0.01||-9.09%||70,650||$0.11||$0.11||$0.11|
|12 May 2022||$0.11||$0.00||0.00%||445,192||$0.12||$0.12||$0.11|
|11 May 2022||$0.11||$0.01||10.20%||496,155||$0.10||$0.11||$0.10|
|10 May 2022||$0.10||$-0.01||-9.09%||2,219,480||$0.11||$0.11||$0.10|
|09 May 2022||$0.11||$0.01||9.52%||48,433||$0.12||$0.12||$0.11|
|06 May 2022||$0.11||$0.00||0.00%||157,421||$0.11||$0.11||$0.11|
|05 May 2022||$0.11||$-0.01||-9.09%||460,269||$0.11||$0.11||$0.11|
|04 May 2022||$0.11||$-0.01||-8.70%||565,625||$0.11||$0.11||$0.11|
|03 May 2022||$0.12||$0.00||0.00%||69,218||$0.12||$0.12||$0.12|
|02 May 2022||$0.12||$0.00||0.00%||163,577||$0.12||$0.12||$0.11|
|29 Apr 2022||$0.12||$0.00||0.00%||142,849||$0.12||$0.12||$0.12|
|28 Apr 2022||$0.12||$-0.01||-8.00%||233,198||$0.12||$0.13||$0.12|
|27 Apr 2022||$0.13||$0.01||8.70%||1,197,144||$0.12||$0.13||$0.12|
|26 Apr 2022||$0.12||$0.00||0.00%||20,000||$0.12||$0.12||$0.12|
|22 Apr 2022||$0.12||$0.01||9.09%||109,653||$0.11||$0.12||$0.11|
|21 Apr 2022||$0.11||$-0.01||-8.70%||510,804||$0.12||$0.12||$0.11|
|20 Apr 2022||$0.12||$0.00||0.00%||119,037||$0.12||$0.12||$0.11|
|Dr Roger Aston||Non-Executive ChairmanNon-Executive Director||May 2012||
Dr Aston has more than 20 years' experience in the pharmaceutical and biotechnology industries. Dr Aston was previously the chief executive officer and a director of Mayne Pharma Group Limited (ASX: MYX). Prior to his position at Mayne Pharma, some of his previous positions have included chief executive officer of Peptech Limited (ASX: PTD), director of Cambridge Antibody Technology Limited (LSE: CAT and NASDAQ: CATG) and chairman of Bio Focus Plc (formerly: Cambridge Drug Discovery Limited). Dr Aston was also founder and chief executive officer of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr Aston has been closely involved in the development of many pharmaceutical and biotechnology companies. He has experience including negotiating global licence agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. He is a member of the Risk committee.
|Mr Paul Brennan||Non-Executive Director||Mar 2022||
Mr Brennan has experience in the health system through his clinical background and experience in commercialisation of technology, company governance, strategic planning and international marketing with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021. Prior to this Mr Brennan was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for 6 years.
|Mr Daniel Pollock||Non-Executive Director||Oct 2012||
Mr Pollock is a sole practitioner in his own legal firm based in Melbourne which operates internationally and specialises in commercial law. Further, he is executive director and co-owner of Great Accommodation Pty Ltd, a property management business operating in Victoria. Mr Pollock has had historical involvement as a seed investor and board member of a number of small unlisted companies. The most recent of these was an e-pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company. He is chair of risk committee.
|Mr Stephen Anastasiou||Non-Executive Director||May 2013||
Mr Anastasiou has over 20 years experience in general management, marketing and strategic planning within the healthcare industry. His experience incorporates medical diagnostics, pharmaceuticals, hospital, dental and over-the-counter products, with companies including the international pharmaceutical company Bristol-Myers Squibb (NYSE: BMY). While working with KPMG Peat Marwick as a management consultant, Mr Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr Anastasiou's companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.
|Mr Ravi Savarirayan||Non-Executive Director||Apr 2017||
Prof Savarirayan has been a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as professor and research group leader of skeletal biology and disease at the Murdoch Children's Research Institute since September 2000. Prof Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has been the chair of the specialist advisory committee in clinical genetics at the Royal Australasian College of Physicians since February 2009. He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several international working committees on constitutional diseases of bone. Prof. Savarirayan's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis and he leads numerous clinical therapy trials for these conditions. He has published over 180 peer-reviewed articles, collaborating with peers from over 30 countries. He has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since July 2007, American Journal of Medical Genetics since December 2011 and the Journal of Medical Genetics since June 2005. He was recently named one of the "Brilliant Minds" of the Murdoch Children's Research Institute over the past 30 years.
|Mr Phillip Hains||Chief Financial OfficerCompany Secretary||Apr 2013||
|Dr Jerry Kanellos||Chief Executive Officer||Mar 2020||
|Jerry Kanellos||Chief Executive Officer||
|Phillip Hains||Chief Financial OfficerCompany Secretary||
|HSBC Custody Nominees (Australia) Limited||98,045,283||43.14%|
|Authentics Australia Pty Ltd <Authentics Australia A/C>||7,000,000||3.08%|
|Grandlodge Pty Ltd||4,931,682||2.17%|
|Dr Russell Kay Hancock||3,000,000||1.32%|
|Mr Stephen Anastasiou & Mrs Andria Anastasiou <Anastasiou Family S/F A/C>||2,494,746||1.10%|
|Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C>||2,000,000||0.88%|
|Gravcon Pty Ltd||1,849,158||0.81%|
|Citicorp Nominees Pty Limited||1,605,473||0.71%|
|Mr William David Frank Bird||1,500,000||0.66%|
|Coin Superannuation Fund Pty Ltd <Coin Super A/C>||1,400,000||0.62%|
|Dr Roger Aston||1,371,376||0.60%|
|Mr Anthony Frederick Wallace Hyett||1,350,000||0.59%|
|Anne Pattison Pty Ltd <Aep No 3 A/C>||1,345,000||0.59%|
|Mr Peter Anastasiou & Mrs Kristine Patricia Anastasiou <Anastasiou Super Fund A/C>||1,332,187||0.59%|
|Mr Iain Chaney & Mrs Antonia Chaney <I & A Chaney Super Fund A/C>||1,235,270||0.54%|
|South Hong Nominees Pty Ltd <Hong Super Fund A/C>||1,200,000||0.53%|
|Fifty-Fifth Leprechaun Pty Ltd <The Andria A/C>||1,079,362||0.48%|
|Karma Wealth Pty Ltd <Lally Family Super Fund A/C>||1,050,000||0.46%|
|Inverarey Pty Ltd <The Kilchurn A/C>||1,050,000||0.46%|
|Karma Wealth Pty Ltd||1,000,000||0.44%|